Aptevo Therapeutics (APVO) Upgraded to Buy at ValuEngine

Aptevo Therapeutics (NASDAQ:APVO) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday.

Several other analysts also recently weighed in on the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $11.00 target price on shares of Aptevo Therapeutics in a research note on Friday, August 10th. Zacks Investment Research raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th.

Shares of NASDAQ APVO opened at $5.27 on Monday. The company has a market capitalization of $109.49 million, a P/E ratio of -3.44 and a beta of 0.21. Aptevo Therapeutics has a 12-month low of $1.15 and a 12-month high of $6.35. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.39 and a current ratio of 4.47.



Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. The company had revenue of $6.83 million during the quarter, compared to the consensus estimate of $4.17 million. research analysts forecast that Aptevo Therapeutics will post -2.63 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in APVO. Renaissance Technologies LLC raised its stake in Aptevo Therapeutics by 411.8% during the 4th quarter. Renaissance Technologies LLC now owns 428,400 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 344,700 shares in the last quarter. Victory Capital Management Inc. raised its stake in Aptevo Therapeutics by 10.3% during the 1st quarter. Victory Capital Management Inc. now owns 215,110 shares of the biotechnology company’s stock valued at $703,000 after acquiring an additional 20,000 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in Aptevo Therapeutics during the 1st quarter valued at $646,000. Spark Investment Management LLC raised its stake in Aptevo Therapeutics by 82.8% during the 1st quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock valued at $423,000 after acquiring an additional 58,600 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Aptevo Therapeutics by 346.6% during the 1st quarter. JPMorgan Chase & Co. now owns 254,282 shares of the biotechnology company’s stock valued at $832,000 after acquiring an additional 197,341 shares in the last quarter. 34.49% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Recommended Story: Average Daily Trade Volume Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply